X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DR. DATSONS LABS - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DR. DATSONS LABS DISHMAN PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 25.1 -10.9 - View Chart
P/BV x 3.3 0.2 2,061.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DR. DATSONS LABS
Mar-14
DISHMAN PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs374126 298.1%   
Low Rs12931 417.2%   
Sales per share (Unadj.) Rs197.8133.0 148.7%  
Earnings per share (Unadj.) Rs21.20.2 13,987.0%  
Cash flow per share (Unadj.) Rs34.76.6 525.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9128.8 139.7%  
Shares outstanding (eoy) m80.6931.66 254.9%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x1.30.6 216.2%   
Avg P/E ratio x11.9516.1 2.3%  
P/CF ratio (eoy) x7.211.8 61.2%  
Price / Book Value ratio x1.40.6 230.2%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3062,477 819.6%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,35556 9,562.3%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,9614,211 379.1%  
Other income Rs m26579 337.2%   
Total revenues Rs m16,2264,289 378.3%   
Gross profit Rs m4,103569 721.6%  
Depreciation Rs m1,091204 533.6%   
Interest Rs m944430 219.5%   
Profit before tax Rs m2,33413 18,374.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-2 -61.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6246 10,223.0%   
Profit after tax Rs m1,7115 35,647.9%  
Gross profit margin %25.713.5 190.4%  
Effective tax rate %26.748.0 55.6%   
Net profit margin %10.70.1 9,404.2%  
BALANCE SHEET DATA
Current assets Rs m11,0186,852 160.8%   
Current liabilities Rs m9,5176,711 141.8%   
Net working cap to sales %9.43.3 280.8%  
Current ratio x1.21.0 113.4%  
Inventory Days Days110161 68.7%  
Debtors Days Days35318 10.9%  
Net fixed assets Rs m16,3043,673 443.9%   
Share capital Rs m161317 51.0%   
"Free" reserves Rs m12,9073,761 343.2%   
Net worth Rs m14,5164,078 356.0%   
Long term debt Rs m4,1891,671 250.7%   
Total assets Rs m29,80512,633 235.9%  
Interest coverage x3.51.0 337.1%   
Debt to equity ratio x0.30.4 70.4%  
Sales to assets ratio x0.50.3 160.7%   
Return on assets %8.93.4 258.7%  
Return on equity %11.80.1 10,013.7%  
Return on capital %17.57.7 228.5%  
Exports to sales %24.822.9 108.3%   
Imports to sales %3.714.3 26.1%   
Exports (fob) Rs m3,956964 410.4%   
Imports (cif) Rs m596602 99.1%   
Fx inflow Rs m4,952964 513.6%   
Fx outflow Rs m697607 114.8%   
Net fx Rs m4,255357 1,192.1%   
CASH FLOW
From Operations Rs m2,7861,345 207.2%  
From Investments Rs m-1,529-2,256 67.8%  
From Financial Activity Rs m-941-1,200 78.4%  
Net Cashflow Rs m316-2,111 -15.0%  

Share Holding

Indian Promoters % 61.4 4.5 1,355.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.0 -  
FIIs % 12.7 1.4 940.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 94.1 23.5%  
Shareholders   46,261 20,807 222.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - ALEMBIC LTD COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS